About Escient Pharmaceuticals
Escient Pharmaceuticals is a company based in San Diego (United States) founded in 2017 was acquired by Incyte in April 2024. Escient Pharmaceuticals has raised $237.5 million across 3 funding rounds from investors including Incyte, TD Securities and Perceptive Advisors. The company has 44 employees as of December 31, 2021. Escient Pharmaceuticals offers products and services including EP262 and EP547. Escient Pharmaceuticals operates in a competitive market with competitors including Aclaris Therapeutics, Nimbus Therapeutics, Alpine Immune Sciences, Septerna and Upstream Bio, among others.
- Headquarter San Diego, United States
- Employees 44 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Escient Pharmaceuticals, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Escient Pharmaceuticals
Escient Pharmaceuticals offers a comprehensive portfolio of products and services, including EP262 and EP547.
Antagonist for MRGPRX2 targeting chronic urticaria and mast cell disorders
Antagonist for MRGPRX4 treating cholestatic pruritus
People of Escient Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of Escient Pharmaceuticals
Escient Pharmaceuticals has successfully raised a total of $237.5M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $120 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Escient Pharmaceuticals
Escient Pharmaceuticals has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Incyte, TD Securities and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Early stage venture capital firm investing in US
|
Locked | Locked | Locked | |
|
Limited information is provided about Forge Life Science Partners.
|
Locked | Locked | Locked |
Investor details for Escient Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Escient Pharmaceuticals
Investment portfolio details for Escient Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Escient Pharmaceuticals
Detailed financials for Escient Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Escient Pharmaceuticals Comparisons
Peer comparison for Escient Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Escient Pharmaceuticals
Escient Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Nimbus Therapeutics, Alpine Immune Sciences, Septerna and Upstream Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
GPCR drug discovery platform is developed for multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for allergic and inflammatory diseases are developed.
|
Detailed competitors of Escient Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Escient Pharmaceuticals
Complete news archive for Escient Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Escient Pharmaceuticals
Escient Pharmaceuticals was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Escient Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Escient Pharmaceuticals is a funded company, having raised a total of $237.5M across 3 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Escient Pharmaceuticals is 44.
Escient Pharmaceuticals was founded in 2017 in San Diego, United States. Small molecule-based therapeutics are developed by the company within the pharmaceutical sector, targeting inflammatory diseases. G protein-coupled receptor (GPCR) drugs are pursued for treating neuro-immuno-inflammatory and autoreactive conditions. Operations center on drug development for these therapeutic areas, with a focus on broad-range applications in immunology and neurology.
Escient Pharmaceuticals's top competitors include Nimbus Therapeutics, Alpine Immune Sciences and Gossamer Bio.
Escient Pharmaceuticals offers EP262 and EP547.
Escient Pharmaceuticals has 15 investors. Key investors include Incyte, TD Securities, Perceptive Advisors, Abingworth, and The Column Group.